 |
|
CLINICIAN'S CORNER
Mixed Dementia
Emerging Concepts and Therapeutic Implications
Kenneth M. Langa, MD, PhD;
Norman L. Foster, MD;
Eric B. Larson, MD, MPH
JAMA. 2004;292:2901-2908.
Context The prevalence of mixed dementia, defined as the coexistence of Alzheimer disease (AD) and vascular dementia (VaD), is likely to increase as the population ages.
Objectives To provide an overview of the diagnosis, pathophysiology, and interaction of AD and VaD in mixed dementia, and to provide a systematic literature review of the current evidence for the pharmacologic therapy of mixed dementia.
Data Sources, Study Selection, and Data Extraction The Cochrane Database of Systematic Reviews was searched using the keyword dementia. MEDLINE was searched for English-language articles published within the last 10 years using the keywords mixed dementia, the combination of keywords Alzheimer disease, cerebrovascular disorders, and drug therapy, and the combination of keywords vascular dementia and drug therapy.
Evidence Synthesis Dementia is more likely to be present when vascular and AD lesions coexist, a situation that is especially common with increasing age. The measured benefits in clinical trials for the treatment of mixed dementia are best described as statistically significant differences in cognitive test scores and clinician and caregiver impressions of change. In these studies, the control groups’ scores typically decline while the treatment groups improve slightly or decline to a lesser degree over the study period. Nevertheless, even the patients who experience treatment benefits eventually decline. Cholinesterase inhibitor (ChI) therapy for mixed dementia shows modest clinical benefits that are similar to those found for ChI treatment of AD. The N-methyl-D-aspartate (NMDA) antagonist memantine also shows modest clinical benefits for the treatment of moderate to severe AD and mild to moderate VaD, but it has not been studied specifically in mixed dementia. The treatment of cardiovascular risk factors, especially hypertension, may be a more effective way to protect brain function as primary, secondary, and tertiary prevention for mixed dementia.
Conclusions Currently available medications provide only modest clinical benefits once a patient has developed mixed dementia. Cardiovascular risk factor control, especially for hypertension and hyperlipidemia, as well as other interventions to prevent recurrent stroke, likely represent important strategies for preventing or slowing the progression of mixed dementia. Additional research is needed to define better what individuals and families hope to achieve from dementia treatment and to determine the most appropriate use of medication to achieve these goals.
Author Affiliations: Division of General Medicine, Department of Medicine, University of Michigan Medical School (Dr Langa), Department of Veterans Affairs Center for Practice Management and Outcomes Research (Dr Langa), and SGIM Collaborative Center for Research and Education in the Care of Older Adults (Dr Langa), and Department of Neurology (Dr Foster), University of Michigan, and the Institute for Social Research and Patient Safety Enhancement Program (Dr Langa), Ann Arbor; and Group Health Cooperative Center for Health Studies, Division of General Internal Medicine, University of Washington (Dr Larson), Seattle.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider et al.
Neurology 2007;69:2197-2204.
ABSTRACT
| FULL TEXT
Dementia and Comorbidities: An Overview of Diagnosis and Management
Swanson and Carnahan
Journal of Pharmacy Practice 2007;20:296-317.
ABSTRACT
Cerebrovascular Reactivity and Cognitive Decline in Patients With Alzheimer Disease
Silvestrini et al.
Stroke 2006;37:1010-1015.
ABSTRACT
| FULL TEXT
Update in neurology.
Holloway and Jozefowicz
ANN INTERN MED 2006;144:421-426.
FULL TEXT
Ageing and the brain
Peters
Postgrad. Med. J. 2006;82:84-88.
ABSTRACT
| FULL TEXT
Heart Disease and Dementia: A Population-based Study
Bursi et al.
Am J Epidemiol 2006;163:135-141.
ABSTRACT
| FULL TEXT
An Editorial Update: Annus horribilis for Vitamin E
Guallar et al.
ANN INTERN MED 2005;143:143-145.
FULL TEXT
Neuroimaging in dementia
Hughes and MacEwan
Psychiatr. Bull. 2005;29:233-233.
FULL TEXT
Dementia Assessment Should Include Cardiovascular Issues
Milne
Psychiatr. News 2005;40:43-48.
FULL TEXT
|
